| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.77B | 5.77 | 59.36 | 43.5% | 9.32% | 1.85% | ||
| CORTCorcept Therapeutics Incorporated | 3.93B | 37.36 | 30.37 | 39.94% | 14.19% | 16.65% | 4.98% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 306.74M | 2.00 | -1.23 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 428.81M | 1.18 | -1.87 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 232.75M | 2.51 | -2.56 | -52.45% | 0.01 | |||
| BIOABioAge Labs, Inc. | 640.01M | 17.85 | -2.69 | -12.81% | -27.32% | 0.03 | ||
| MISTMilestone Pharmaceuticals Inc. | 166.93M | 1.96 | -2.93 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 422.59M | 4.05 | -3.02 | -95.31% | -4195.75% | -45.21% | 0.01 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 151K | 1.07M |
| Revenue Growth % | - | - | 6.12% |
| Cost of Goods Sold | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 151K | 1.07M |
| Gross Margin % | - | 1% | 1% |
| Gross Profit Growth % | - | - | 6.12% |
| Operating Expenses | 27.97M | -1.92M | 81.9M |
| OpEx % of Revenue | - | -12.74% | 76.18% |
| Selling, General & Admin | 5.92M | 9.72M | 16.56M |
| SG&A % of Revenue | - | 64.38% | 15.41% |
| Research & Development | 22.04M | 35.98M | 65.34M |
| R&D % of Revenue | - | 238.27% | 60.78% |
| Other Operating Expenses | 0 | -47.63M | 0 |
| Operating Income | -27.97M | 2.08M | -80.82M |
| Operating Margin % | - | 13.74% | -75.18% |
| Operating Income Growth % | - | 1.07% | -39.95% |
| EBITDA | -27.39M | 2.92M | -79.42M |
| EBITDA Margin % | - | 19.36% | -73.88% |
| EBITDA Growth % | - | 1.11% | -28.17% |
| D&A (Non-Cash Add-back) | 577K | 848K | 1.4M |
| EBIT | -27.97M | -45.55M | -80.82M |
| Net Interest Income | 291K | 2.79M | 8.62M |
| Interest Income | 291K | 2.79M | 8.62M |
| Interest Expense | 0 | 0 | 0 |
| Other Income/Expense | 291K | 2.8M | 8.53M |
| Pretax Income | -27.68M | 4.87M | -72.3M |
| Pretax Margin % | - | 32.26% | -67.25% |
| Income Tax | 0 | 691K | -498K |
| Effective Tax Rate % | 1% | 0.86% | 0.99% |
| Net Income | -27.68M | 4.18M | -71.8M |
| Net Margin % | - | 27.68% | -66.79% |
| Net Income Growth % | - | 1.15% | -18.18% |
| Net Income (Continuing) | -27.68M | 4.18M | -71.8M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -1.42 | 0.03 | -7.26 |
| EPS Growth % | - | 1.02% | -250.48% |
| EPS (Basic) | -1.42 | 0.03 | -7.26 |
| Diluted Shares Outstanding | 19.5M | 19.5M | 9.89M |
| Basic Shares Outstanding | 19.5M | 19.5M | 9.89M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 31.89M | 112.68M | 356.82M |
| Cash & Short-Term Investments | 30.61M | 88.48M | 350.92M |
| Cash Only | 30.61M | 88.48M | 238.2M |
| Short-Term Investments | 0 | 0 | 112.73M |
| Accounts Receivable | 0 | 22.78M | 1.12M |
| Days Sales Outstanding | - | 55.05K | 381.64 |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 204K | 92K | 200K |
| Total Non-Current Assets | 4.23M | 18.19M | 99.73M |
| Property, Plant & Equipment | 3.1M | 17.19M | 28.69M |
| Fixed Asset Turnover | - | 0.01x | 0.04x |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 69.87M |
| Other Non-Current Assets | 1.12M | 1M | 1.17M |
| Total Assets | 36.12M | 130.87M | 456.55M |
| Asset Turnover | - | 0.00x | 0.00x |
| Asset Growth % | - | 2.62% | 2.49% |
| Total Current Liabilities | 5.54M | 6.91M | 12.85M |
| Accounts Payable | 3.07M | 2.64M | 3.2M |
| Days Payables Outstanding | - | - | - |
| Short-Term Debt | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 1.76M | 3.04M | 4.21M |
| Current Ratio | 5.75x | 16.30x | 27.77x |
| Quick Ratio | 5.75x | 16.30x | 27.77x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 74.78M | 162.33M | 23.66M |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 12.57M | 23.63M |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 74.78M | 149.76M | 33K |
| Total Liabilities | 80.32M | 169.24M | 36.51M |
| Total Debt | 710K | 12.57M | 25.48M |
| Net Debt | -29.9M | -75.92M | -212.72M |
| Debt / Equity | - | - | 0.06x |
| Debt / EBITDA | - | 4.30x | - |
| Net Debt / EBITDA | - | -25.97x | - |
| Interest Coverage | - | - | - |
| Total Equity | -44.2M | -38.37M | 420.05M |
| Equity Growth % | - | 0.13% | 11.95% |
| Book Value per Share | -2.27 | -1.97 | 42.47 |
| Total Shareholders' Equity | -44.2M | -38.37M | 420.05M |
| Common Stock | 3K | 3K | 44K |
| Retained Earnings | -50.76M | -46.58M | -118.37M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 56K |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -23.3M | -38.72M | -67.47M |
| Operating CF Margin % | - | -256.44% | -62.76% |
| Operating CF Growth % | - | -0.66% | -0.74% |
| Net Income | -27.68M | 4.18M | -71.8M |
| Depreciation & Amortization | 577K | 848K | 1.4M |
| Stock-Based Compensation | 1.52M | 1.62M | 3.15M |
| Deferred Taxes | 0 | 491K | -491K |
| Other Non-Cash Items | 530K | -46.79M | 18K |
| Working Capital Changes | 1.75M | 926K | 248K |
| Change in Receivables | 0 | -151K | -20K |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 1.73M | -653K | 723K |
| Cash from Investing | -1.29M | 22.12M | -160.6M |
| Capital Expenditures | -1.29M | -2.88M | -2.1M |
| CapEx % of Revenue | - | 19.06% | 1.96% |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | 0 | 25M | 22.63M |
| Cash from Financing | 30.05M | 74.52M | 377.78M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | 82K | 0 | 52K |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -24.59M | -41.6M | -69.57M |
| FCF Margin % | - | -275.5% | -64.72% |
| FCF Growth % | - | -0.69% | -0.67% |
| FCF per Share | -1.26 | -2.13 | -7.03 |
| FCF Conversion (FCF/Net Income) | 0.84x | -9.26x | 0.94x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 75K | 232K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Return on Equity (ROE) | - | - | -37.62% |
| Return on Invested Capital (ROIC) | - | - | -130.31% |
| Gross Margin | - | 100% | 100% |
| Net Margin | - | 2768.21% | -6678.88% |
| Debt / Equity | - | - | 0.06x |
| FCF Conversion | 0.84x | -9.26x | 0.94x |
| Revenue Growth | - | - | 611.92% |
Septerna, Inc. (SEPN) reported $22.0M in revenue for fiscal year 2024.
Septerna, Inc. (SEPN) grew revenue by 611.9% over the past year. This is strong growth.
Septerna, Inc. (SEPN) reported a net loss of $58.8M for fiscal year 2024.
Septerna, Inc. (SEPN) has a return on equity (ROE) of -37.6%. Negative ROE indicates the company is unprofitable.
Septerna, Inc. (SEPN) generated $103.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.